Targeting c-Myc enhances immunotherapy efficacy in combination with Ras inhibitor in triple-negative breast cancer.

ABSTRACT:

Background

Triple-negative breast cancer (TNBC), which lacks hormone receptors and HER2 expression, presents substantial therapeutic challenges in breast cancer treatment. The efficacy of immunotherapy frequently suffers from the immunosuppressive nature of tumour microenvironment (TME). Hence, discovering effective targets to hinder TNBC progression and bolster immunotherapy's effectiveness is paramount. Previous research from our team indicated notable upregulation of c-Myc in TNBC, and suppressing c-Myc enhances the efficacy of PD-L1 blockade in murine models; nevertheless, the precise mechanisms underlying this phenomenon remain elusive.

Methods

We analysed c-Myc expression and implemented a systematic drug library screening strategy alongside c-Myc knockdown to pinpoint

SUBMITTER: Liang X 

PROVIDER: S-EPMC12477544 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature